- Home
- SEEL
as 07-26-2024 4:00pm EST
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.4M | IPO Year: | N/A |
| Target Price: | $240.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -82.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $398.40 | Next Earning Date: | 08-12-2024 |
| Revenue: | $1,974,000 | Revenue Growth: | 144.31% |
| Revenue Growth (this year): | -86.11% | Revenue Growth (next year): | 9366.67% |
Stock Insider Trading Activity of Seelos Therapeutics Inc. (SEEL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mehra Raj | SEEL | See Remarks | Dec 1 '23 | Buy | $1.32 | 75,757 | $99,999.24 | 185,142 | SEC Form 4 |
| Golembiewski Michael Joseph | SEEL | Chief Financial Officer | Nov 30 '23 | Buy | $1.21 | 83,000 | $100,222.50 | 86,450 | SEC Form 4 |
Latest Seelos Therapeutics Inc. News
SEEL Breaking Stock News: Dive into SEEL Ticker-Specific Updates for Smart Investing
PR Newswire
2 months ago
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
MT Newswires
2 months ago
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance
PR Newswire
2 months ago
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
Associated Press Finance
2 months ago
Seelos: Q1 Earnings Snapshot
PR Newswire
3 months ago
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Reuters
4 months ago
UPDATE 1-Seelos Therapeutics' ALS treatment fails in mid-stage study
Reuters
4 months ago
Seelos says ALS treatment fails in mid-stage study
PR Newswire
4 months ago
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Compare SEEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SEEL Seelos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.